Of Cancer published by John Wiley Sons Ltd on behalf of

Kaplan eier survival curves illustrating differences in time to relapse (left GW433908G web panels) and disease-specific survival (right panels) after liver surgery for metastatic colorectal cancer comparing patients STA-9090 harboring no mutations to patients harboring intraindividual mutation heterogeneity across either KRAS, BRAF, TP53 or PI3K and patients revealing at least one homogenous but no heterogeneous mutation in either gene (a). double wt) Chemotherapy1 1.08 0.93 1.55 2.00 1.73 0.92 1.12 2.34 0.39 95 CI (0.71, 1.65) (0.62, 1.40) (0.97, 2.48) (1.21, 3.29) (1.11, 2.68) (0.61,1.42) (0.63, 1.97) (1.50, 3.66) (0.23, 0.64) p values 0.720 0.726 0.064 0.007 0.015 0.720 0.700 title= 1479-5868-9-35 patients harboring a homogeneous mutation in at least one gene across all metastatic deposits and with no heterogeneous mutation and (iii) patients with no mutations across either gene. Comparing all three groups, univariate analysis revealed asignificant different TTR (median of 4 vs. 5 vs. 15 months, p title= ejsp.2064 58 months, p